Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 3Lung Neoplasms 2Adenocarcinoma of Lung 2Pleural Effusion, Malignant 1NSCLC 1

Interventions

Drug Therapy 3Carboplatin 3Surgical Procedures, Operative 2Pemetrexed 2Paclitaxel 2Cisplatin 2toripalimab 1tislelizumab 1surufatinib 1osimertinib 1lorlatinib 1anlotinib 1aflutinib 1Radiotherapy 1Radiosurgery 1Platinum Compounds 1Neoadjuvant Therapy 1Diphenhydramine 1Cryotherapy 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NSCLC × aflutinib × Clear all
NCT07622706 2026-06-03

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
60 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡